Literature DB >> 11535128

Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.

G Høyer-Hansen1, U Pessara, A Holm, J Pass, U Weidle, K Danø, N Behrendt.   

Abstract

Urokinase (uPA) has the striking ability to cleave its receptor, uPAR, thereby inactivating the binding potential of this molecule. Here we demonstrate that the glycosylphosphatidylinositol (GPI) anchor of uPAR, which is attached to the third domain, is an important determinant in governing this reaction, even though the actual cleavage occurs between the first and second domains. Purified full-length GPI-anchored uPAR (GPI-uPAR) proved much more susceptible to uPA-mediated cleavage than recombinant truncated soluble uPAR (suPAR), which lacks the glycolipid anchor. This was not a general difference in proteolytic susceptibility since GPI-uPAR and suPAR were cleaved with equal efficiency by plasmin. Since the amino acid sequences of GPI-uPAR and suPAR are identical except for the C-terminal truncation, the different cleavage patterns suggest that the two uPAR variants differ in the conformation or the flexibility of the linker region between domains 1 and 2. This was supported by the fact that an antibody to the peptide AVTYSRSRYLE, amino acids 84-94 in the linker region, recognizes GPI-uPAR but not suPAR. This difference in the linker region is thus caused by a difference in a remote hydrophobic region. In accordance with this model, when the hydrophobic lipid moiety was removed from the glycolipid anchor by phospholipase C, low concentrations of uPA could no longer cleave the modified GPI-uPAR and the reactivity to the peptide antibody was greatly decreased. Naturally occurring suPAR, purified from plasma, was found to have a similar resistance to uPA cleavage as phospholipase C-treated GPI-uPAR and recombinant suPAR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535128      PMCID: PMC1222101          DOI: 10.1042/0264-6021:3580673

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

Review 1.  The glycosyl-phosphatidylinositol anchor of membrane proteins.

Authors:  M G Low
Journal:  Biochim Biophys Acta       Date:  1989-12-06

2.  Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.

Authors:  B Degryse; M Resnati; S A Rabbani; A Villa; F Fazioli; F Blasi
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

3.  Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.

Authors:  E Rønne; N Behrendt; V Ellis; M Ploug; K Danø; G Høyer-Hansen
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

4.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

Authors:  N Behrendt; E Rønne; M Ploug; T Petri; D Løber; L S Nielsen; W D Schleuning; F Blasi; E Appella; K Danø
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

5.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol.

Authors:  M Ploug; E Rønne; N Behrendt; A L Jensen; F Blasi; K Danø
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

6.  Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.

Authors:  G Høyer-Hansen; E Rønne; H Solberg; N Behrendt; M Ploug; L R Lund; V Ellis; K Danø
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

7.  Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.

Authors:  M Ploug; M Kjalke; E Rønne; U Weidle; G Høyer-Hansen; K Danø
Journal:  J Biol Chem       Date:  1993-08-15       Impact factor: 5.157

8.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.

Authors:  H Solberg; D Løber; J Eriksen; M Ploug; E Rønne; N Behrendt; K Danø; G Høyer-Hansen
Journal:  Eur J Biochem       Date:  1992-04-15

10.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.

Authors:  N Behrendt; M Ploug; L Patthy; G Houen; F Blasi; K Danø
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

View more
  18 in total

1.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

2.  Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures.

Authors:  Yifan Ge; Amanda P Siegel; Rainer Jordan; Christoph A Naumann
Journal:  Biophys J       Date:  2014-11-04       Impact factor: 4.033

3.  Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.

Authors:  Nels C Olson; Laura M Raffield; Anne H Moxley; Tyne W Miller-Fleming; Paul L Auer; Nora Franceschini; Debby Ngo; Timothy A Thornton; Ethan M Lange; Yun Li; Deborah A Nickerson; Neil A Zakai; Robert E Gerszten; Nancy J Cox; Adolfo Correa; Karen L Mohlke; Alexander P Reiner
Journal:  Circ Genom Precis Med       Date:  2021-10-28

4.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

Review 5.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

6.  Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions.

Authors:  Orla Cunningham; Annapaola Andolfo; Maria Lisa Santovito; Lucia Iuzzolino; Francesco Blasi; Nicolai Sidenius
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

7.  The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.

Authors:  Dominique Leduc; Nathalie Beaufort; Sophie de Bentzmann; Jean-Claude Rousselle; Abdelkader Namane; Michel Chignard; Dominique Pidard
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

8.  Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.

Authors:  Efrat Harel; Jun Shoji; Vivek Abraham; Loan Miller; Zoltan G Laszik; Andrew King; Dejan Dobi; Gyula Szabo; Byron Hann; Minnie M Sarwal; Charles S Craik; Flavio Vincenti
Journal:  Transplantation       Date:  2020-01       Impact factor: 5.385

9.  Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

Authors:  A F Lomholt; G Høyer-Hansen; H J Nielsen; I J Christensen
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

10.  Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.

Authors:  Line H Dohn; Peter Thind; Lisbeth Salling; Henriette Lindberg; Sofie Oersted; Ib J Christensen; Ole D Laerum; Martin Illemann; Hans von der Maase; Gunilla Høyer-Hansen; Helle Pappot
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.